Table 1.
Patient baseline characteristics.
| Characteristic | All Patients n = 72 | Patients with Metastatic Disease n = 53 |
|---|---|---|
| Sex, n (%) | ||
| Male | 36 (50) | 22 (42) |
| Female | 36 (50) | 31 (58) |
| Age, years, n (%) | ||
| <5 | 10 (14) | 1 (2) |
| 5 to <18 | 11 (15) | 10 (19) |
| ≥18 | 51 (71) | 42 (79) |
| ECOG performance status, n (%) | ||
| 0 | 35 (49) | 22 (42) |
| 1 | 28 (39) | 23 (43) |
| 2 | 9 (13) | 8 (15) |
| Disease setting, n (%) | ||
| Locally advanced | 19 (26) | 0 |
| Metastatic | 53 (74) | 53 (100) |
| Tumor type, n (%) | ||
| STS: Infantile fibrosarcoma | 10 (14) | 3 (6) |
| STS: Other | 16 (22) | 12 (23) |
| Salivary gland | 9 (13) | 4 (8) |
| Lung cancer | 7 (10) | 7 (13) |
| Melanoma | 7 (10) | 5 (9) |
| Thyroid cancer | 7 (10) | 6 (11) |
| Colon cancer | 6 (8) | 6 (11) |
| Gastrointestinal stromal tumor | 4 (6) | 4 (8) |
| Cholangiocarcinoma | 2 (3) | 2 (4) |
| Appendix cancer | 1 (1) | 1 (2) |
| Bone sarcoma | 1 (1) | 1 (2) |
| Breast cancer | 1 (1) | 1 (2) |
| Pancreatic cancer | 1 (1) | 1 (2) |
| Prior lines of treatment for advanced disease, n (%) | ||
| 0 | 0 | 0 |
| 1 | 26 (36) | 13 (25) |
| 2 | 20 (28) | 16 (30) |
| ≥3 | 26 (36) | 24 (45) |
| NTRK gene fusion, n (%) | ||
| NTRK1 | 35 (49) | 29 (55) |
| NTRK2 | 2 (3) | 2 (4) |
| NTRK3 | 35 (49) | 22 (42) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NTRK, neurotrophic tyrosine receptor kinase; STS, soft tissue sarcoma.